EVAXION BIOTECH A/S - Group

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 0.0% 4.5% 12.3%  
Credit score (0-100)  0 0 0 46 18  
Credit rating  N/A N/A N/A BBB BB  
Credit limit (kDKK)  0.5 0.0 0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 507  
Gross profit  0.0 0.0 0.0 0.0 507  
EBITDA  0.0 0.0 0.0 -178,736 -152,895  
EBIT  0.0 0.0 0.0 -178,736 -152,895  
Pre-tax profit (PTP)  -11.2 0.0 0.0 -169,720.0 -157,855.0  
Net earnings  -11.2 0.0 0.0 -164,292.0 -152,414.0  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 -169,720 -157,855  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 32,601 29,293  
Shareholders equity total  0.0 0.0 0.0 57,888 -31,893  
Interest-bearing liabilities  0.0 0.0 0.0 55,778 58,331  
Balance sheet total (assets)  9.6 0.0 0.0 153,575 86,928  

Net Debt  -9.6 0.0 0.0 -36,145 20,680  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 507  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 0.0 507  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 62 55  
Employee growth %  0.0% 0.0% 0.0% 0.0% -11.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  10 0 0 153,575 86,928  
Balance sheet change%  12.3% -100.0% 0.0% 0.0% -43.4%  
Added value  0.0 0.0 0.0 -178,736.0 -152,895.0  
Added value %  0.0% 0.0% 0.0% 0.0% -30,156.8%  
Investments  -0 0 0 32,601 -3,308  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 -1.0 -2.0  

Profitability 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% -30,156.8%  
EBIT %  0.0% 0.0% 0.0% 0.0% -30,156.8%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 0.0% -30,156.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% -30,061.9%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% -30,061.9%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% -31,135.1%  
ROA %  0.0% 0.0% 0.0% -103.4% -107.4%  
ROI %  0.0% 0.0% 0.0% -123.8% -145.9%  
ROE %  2,404.9% 0.0% 0.0% -283.8% -210.5%  

Solidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 0.0% 74.0% 30.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 23,237.5%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 15,811.2%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 20.2% -13.5%  
Gearing %  0.0% 0.0% 0.0% 96.4% -182.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 39.0% 20.4%  

Liquidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 4.5 1.2  
Current Ratio  0.0 0.0 0.0 4.5 1.2  
Cash and cash equivalent  9.6 0.0 0.0 91,923.0 37,651.0  

Capital use efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 11,106.5%  
Net working capital  9.6 0.0 0.0 92,186.0 8,544.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 1,685.2%  

Employee efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 9  
Added value / employee  0 0 0 -2,883 -2,780  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -2,883 -2,780  
EBIT / employee  0 0 0 -2,883 -2,780  
Net earnings / employee  0 0 0 -2,650 -2,771